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Abstract 
The  protein  insulin-like  growth  factor  II
mRNA binding protein 3 (IMP-3) is an impor-
tant factor for cell migration and adhesion in
malignancies.  Recent  studies  have  shown  a
remarkable overexpression of IMP-3 in different
human malignant neoplasms and also revealed
it as an important prognostic marker in some
tumor entities. The purpose of this study is to
compare IMP-3 immunostaining in cutaneous
squamous cell tumors and determine whether
IMP-3 can aid in the differential diagnosis of
these lesions. To our knowledge, IMP-3 expres-
sion has not been investigated in skin squa-
mous  cell  proliferations  thus  far.  Immunohi  -
stochemical staining for IMP-3 was performed
on  slides  organized  by  samples  from  67
patients, 34 with keratoacanthoma (KA) and 33
with primary cutaneous squamous cell carcino-
ma (SCC) (16 invasive and 17 in situ). Seventy-
four percent of KAs (25/34) were negative for
IMP-3 staining, while 57% of SCCs (19/33) were
positive for IMP-3 staining. The percentage of
IMP-3 positive cells increased significantly in
the invasive SCC group (P=0.0111), and partic-
ularly in the SCC in situ group (P=0.0021) with
respect to the KA group. IMP-3 intensity stain-
ing was significantly higher in invasive SCCs
(P=0.0213),  and  particularly  in  SCCs  in  situ
(P=0.008) with respect to KA. Our data show
that IMP-3 expression is different in keratoa-
canthoma with respect to squamous cell carci-
noma. IMP-3 assessment and staining pattern,
together with a careful histological study, can be
useful in the differential diagnosis between KA
e SCC.
Introduction
Insulin-like growth factor-II (IGF-II) messen-
ger  RNA  (mRNA)-binding  protein-3  (IMP-3),
also known as K homology domain-containing
protein  overexpressed  in  cancer  (KOC)  and
L523S, is a member of the IGF-II mRNA-binding
protein (IMP) family, which also includes IMP-1
and IMP-2.1 IMP-3 is a 580 amino-acid protein
encoded  by  a  4350-bp  mRNA  transcript  pro-
duced  by  a  gene  located  on  chromosome
7p11.5.2 It is associated with cell proliferation
and is considered an oncofetal protein due to its
expression during embryogenesis and in some
malignancies, including pancreatic carcinoma,
renal  cell  carcinoma,  endometrial  carcinoma,
germ cell neoplasms, ovarian carcinoma, extra-
pulmonary  small-cell  carcinoma,  as  well  as
high-grade  neuroendocrine  carcinoma,  squa-
mous cell carcinoma, and adenocarcinoma of
the lung.3-10 Its exact role in carcinogenesis is
still unclear. 
IMP-3 has been shown to be a prognostic
marker in renal cell carcinoma,5 colorectal car-
cinoma11 and  gastric  adenocarcinoma,12 and
has been proposed as a potential therapeutic
target  for  lung  cancer.13  IMP-3  expression
increases with the degree of dysplasia in the
pancreatic ductal epithelium; it is related to
tumor stage in pancreatic carcinoma3 and to
aggressive behavior of urothelial carcinomas.14
Moreover, IMP-3 has been claimed as a diag-
nostic  clue  in  cutaneous  melanocytic  neo-
plasms  as  it  is  expressed  in  malignant
melanoma but not in benign melanocytic nevi,
even  when  dysplastic  features  are  present.15
Squamous cell carcinoma of head and neck,
tongue and uterine cervix has been shown to
express IMP-316-18 but, to the best of our knowl-
edge, cutaneous squamous cell tumors have
never been investigated.
Keratoacanthoma is an intriguing tumor, by
most considered a benign neoplasm intended
to involute with complete resolution within a
few months. Other authors classify it as a sub-
type of squamous cell carcinoma. In routine
practice,  histologic  and  cytologic  features  of
keratoacantoma and squamous cell carcinoma
are often difficult to distinguish and a reliable
marker to differentiate these lesions has not
been found. The question has been raised as to
whether keratoacanthoma is an unreliable his-
tological  diagnosis  or  these  tumors  have  a
latent, although rare, malignant potential. The
understanding  of  the  nature  of  keratoacan-
thoma has been controversial since its original
description19 between 1950 and 1980. The con-
sensus of the dermatology and dermatopathol-
ogy community has been to classify this lesion
as  a  benign  condition,  although  papers
describing malignant behavior in keratoacan-
thoma have been published.20-24
The  objective  of  this  study  was  to  analyze
immunohistochemical IMP-3 expression in ker-
atoacanthomas  and  cutaneous  squamous  cell
carcinomas to determine whether IMP-3 can aid
in the differential diagnosis of these lesions. 
Materials and Methods
Samples
A retrospective study was initiated to review
the medical records of all patients with a diag-
nosis  of  keratoacantoma  and  squamous  cell
carcinoma  between  2010  and  2011  at  the
Pathology  Division,  University  of  Cagliari,
Italy. Through a careful clinicopathological cor-
relation, we identified 67 squamous cell skin
lesions grouped into 34 cases of keratoacan-
thoma and 33 of squamous cell carcinoma, 17
in  situ and  16  invasive.  Clinicopathological
variables such as patients’ age and sex, maxi-
mum diameter of lesions, growth phase of KA,
ulceration, Clark level and depth of invasion of
SCC were recorded. 
Immunohistochemistry
Five  micron  paraffin  sections  were
immunostained for IMP-3 (code M3626 mon-
oclonal  mouse  anti-Human  IMP-3;  Dako
Cytomation, Carpinteria, CA, USA). We used
the Dako cytomation LSAB2 system-HRP in a
Dako  Autostainer  (Dako  Cytomation).  This
system is based on a technique that employs
a modified labeled avidin-biotin (LAB) where
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a  biotinylated  secondary  antibody  forms  a
complex with peroxidase-coniugated strepta-
vidin  molecules.  Endogenous  peroxidase
activity was quenched by incubating (5 min)
specimens with 3% hydrogen peroxide. Heat-
induced  antigen  retrieval  was  adopted  (20
min at 98° in Tris/EDTA pH9). Tissue sections
were  incubated  (30  min  at  room  tempera-
ture) with the IMP-3 antibody. Staining was
completed  after  incubation  (10  min)  with
AEC  (3-amino-9.ethyl  carbazole,  substrate
chromogen) and it resulted in a red-colored
precipitate  at  the  antigen  site.  Slides  were
reviewed by two pathologists (SS and LP) who
were not aware of the clinical data, and eval-
uated  for  both  tumor  cell  percentage  and
intensity  of  immunoreactivity.  Cytoplasmic
staining  was  considered  positive  for  IMP-3
expression. The percentage of positive cells
was recorded as 0=negative; 1=<5% of cells
stained;  2=5-9.9%  of  cells  stained;  3=10-
49.9%  of  cells  stained;  and  4=50-90%;  and
>90% of cells stained.15 Intensity was scored
as 0 (negative), 1+ (weak), 2+ (moderate),
and 3+ (strong),25 and evaluated by compari-
son with contiguous sebaceous glands (con-
sidered moderately positive).
Statistical analysis 
The  response  variables  involved  in  the
analysis,  such  as  the  percentage  of  positive
cells or their intensity, are of the semiquanti-
tative type, more precisely, they are ordered
polytomous  categorical  values.  Therefore,  of
interest is not their value (i.e., 1, 2, etc.), but
instead their frequency distribution and how it
changes across different values of the predic-
tor variables. To regress such variables over a
specified set of predictors it is more appropri-
ate to use the proportional odds model;26 basi-
cally, this is a generalization of the regression
model for polytomous response variables. The
P-values obtained from the proportional odds
model for the regression coefficients resemble
the evidence for the association between the
specific regressor variable and the polytomous
response one. The preselected significance is
5% (P<0.05). The proportional odds model is a
rather  standard  model  implemented  in  soft-
ware as, for instance, R.27
Results
Clinicopathological features of
squamous skin lesions
Clinical features of squamous skin lesions
recruited in our study are presented in Table 1.
The keratoacanthomas were from 34 subjects
(22 males and 12 females) ranging from 39 to
90 years of age (mean age 69.5). The lesions
consisted  clinically  of  a  firm,  dome-shaped
nodule ranging from 6 to 30 mm in maximum
diameter  with  a  horn-filled  crater.  They
reached their full size with rapid growth in a
period  ranging  from  a  few  weeks  to  some
months.  Histologically,  keratoacanthomas
were  symmetric  exo-endophytic  lesions  with
central  horn-filled  crater  and  overhanging
epithelial  lips,  composed  of  glassy  ker-
atinocytes with intracytoplasmic glycogen and
intraepithelial elastic fibers, characterized by
a sharp outline between tumor and stroma, not
extending to a depth below the eccrine glands.
A rather pronounced mixed inflammatory infil-
trate was present in the surrounding dermis,
sometimes with development of eosinophilic
or  neutrophilic  epithelial  microabscesses.
Keratinocytes  showed  variable  degrees  of
nuclear atypia and mitotic figures, usually con-
fined to the basal layers and more pronounced
in keratoacanthomas in the early proliferative
stage. Perineural or vascular invasion was not
observed in any of our cases. Sixteen cases
had  at  least  partial  features  of  regressing
lesions showing flattening of the central horn-
filled crater.
The 33 squamous cell carcinomas included
17 intraepithelial (in situ) carcinomas (Clark
I) from 9 males and 8 females ranging from 54
to 84 years of age (mean age 74.4) and 16 inva-
sive carcinomas  (3:  Clark  II,  1:  Clark  III,  9:
Clark  IV,  3:  Clark  V)  from  11  males  and  5
females ranging from 63 to 94 years of age
(mean  age  78)  (Tables  1  and  2).  Clinically,
SCCs in situ appeared as slowly enlarging ery-
thematous patches showing little or no infiltra-
tion, with areas of scaling and crusting. Twelve
of  the  selected  invasive  SCCs  presented  as
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Table 1. Clinical data.
N. Max diam. (mm) Sex Age Mean age Median age Site
KA 34 6-30 M (22) 39-90 y 69.5 71.5 Face (11), arm (6), hand (6),trunk (3), thigh (2),
F (12) scalp (2), leg (2), neck (1), shoulder (1)
SCC invasive 16 6-22 M (11) 63-94 y 78,0 77 Face (9), scalp (4), arm (1), ear (1), hand (1)
F (5)
SCC in situ 17 3-25 M (9) 50-84 y 74,4 77 Face (6), leg (5), scalp (2), ear (2), hand (1), trunk (1)
F (8)
KA, keratoacanthoma; SCC, squamous cell carcinoma; M, male; F, female.
ab
Figure 1. Representative staining results in a case of keratoacanthoma. a) H&E staining
showing a squamous cell proliferation with overhanging epithelial lips and numerous
glassy keratinocytes; b) IMP-3 immunohistochemistry was negative. Scale bars: 500 µm.
Table 2. Histologic features of squamous cell carcinomas.
Clark I II III IV V
Cases 17 3193
Breslow (mm) n.a. 0.5-3.1 1 1.5-6.0 4.0-5.4
Ulceration 32172
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ulcerative skin lesions with a keratinous crust
and elevated, indurated surrounding, while 5
of  them  presented  as  nodular  tumors  often
misdiagnosed  as  basal  cell  carcinomas.
Histologically, irrespective of the presence or
absence of ulceration, SCCs were character-
ized by nests of atypical squamous cells with
abundant eosinophilic cytoplasm and a large,
often vesicular nucleus arising from the epi-
dermis  and  invading  the  dermis  to  variable
extent.
IMP-3 expression by
immunohistochemistry
Data on IMP-3 immunohistochemical stain-
ing  are  presented  in  Table  3.  Of  34  KAs,  25
(74%) were negative for IMP-3 staining (Figure
1a,b). Nine positive KAs (6 proliferative and 3
regressing) showed IMP-3 cytoplasmic expres-
sion  in  <50%  of  tumor  cells.  IMP-3  staining
intensity was weak (1+) in six out of nine and
moderate (2+) in three out of nine. The positiv-
ity was usually confined to basal layers of atypi-
cal  keratinocytes  (Figure  2a,b).  The  growth
phase  (proliferative  or  regressing)  was  not
related to IMP-3 expression (P=0.02569). On
the contrary, 19 of 33 SCCs (57%) were IMP-3
positive (8/16 invasive, 11/17 in situ) (Figure 3
a,b; Figure 4a,b). The pattern of IMP-3 expres-
sion in these cases was variable, ranging from
focal and weak to intense and diffuse positivity.
Fourteen of thirty-three SCCs (43%) (8/16 inva-
sive, 6/17 in situ) were completely negative for
IMP-3 (Figure 5a,b). The percentage of IMP3-
positive cells in invasive SCCs was not related
to the three clinicopathological features consid-
ered:  ulceration  (P=0.7152),  Clark  level
(P=0.6924) and depth of invasion (P=0.8695).
Age, sex, and lesion diameter were not related
to  IMP-3  in  any  of  the  groups.  To  compare
immunohistochemical data on KA to SCC, we
found statistical evidence for the percentage of
IMP-3 positive cells to increase significantly in
the invasive SCC group (P=0.0111), and par-
ticularly in the SCC in situ group (P=0.0021)
with respect to the KA group. IMP-3 intensity
staining  increased  significantly  in  invasive
SCCs (P=0.0213), and particularly in SCCs in
situ (P=0.008) with respect to KA. The intensi-
ty was not significantly related to the percent-
age of IMP-3 positive cells.
Discussion
Keratoacanthoma is a controversial lesion
considered either benign or a subtype of squa-
mous cell carcinoma.19 In routine histopatho-
logical examination there are tumors that are
difficult to classify as either KA or SCC.
Helpful  criteria  for  the  diagnosis  of  a  KA
include epithelial lips, a sharp outline between
tumor and stroma and absence of ulceration.28-33
Criteria more commonly seen in SCCs include a
Original Paper
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Figure 5. Representative staining results in a case of squamous cell carcinoma. a) H&E
staining showing a squamous cell ulcerated tumor composed of nests of atypical epithe-
lial cells extending into the dermis; b) IMP-3 staining was negative. Scale bars: 200 µm.
ab
Figure 2. Representative staining results in a case of keratoacanthoma. a) H&E staining
showing a squamous cell proliferation composed of glassy keratinocytes surrounded by a
prominent mixed inflammatory infiltrate; b) IMP-3 staining shows weak and focal posi-
tivity confined to basal atypical keratinocytes. Scale bars: 200 µm.
ab
Figure 3. Representative staining results in a case of invasive squamous cell carcinoma. a)
H&E staining showing a squamous cell ulcerated tumor composed of nests of atypical
epithelial cells extending into the dermis; b) IMP-3 staining shows moderate to intense
diffuse positivity. Scale bars: 200 µm.
ab
Figure 4. Representative staining results in a case of squamous cell carcinoma in situ. a)
H&E staining showing a intraepidermic squamous cell proliferation; b) IMP-3 staining
shows intense and diffuse positivity. Scale bars: 200 µm.
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high  mitotic  index  and  marked  cellular  pleo-
morphism.34Cribier et al.found that 81% of KAs
and 86% of SCCs could be diagnosed using com-
mon criteria; the remainder often showed con-
flicting features, such as a generally crateriform
architecture with prominent nuclear atypia at
the borders of the tumor.34 Many criteria com-
monly used for the differential diagnosis of SCC
and KA are unreliable.35
In  this  challenging  diagnostic  scenario,
many studies have been performed to identify
immunohistochemical and molecular markers
that  might  distinguish  KAs  from  SCCs.
Nonetheless, no marker has yet been found to
differentiate KAs and SCCs with high sensitiv-
ity and specificity.
Immunohistochemical studies showed filag-
grin,  syndecan-1,  E-cadherin,  TGF-alpha,
VCAM (CD-106) and ICAM (CD-54) to be more
expressed in KA36-42 while a stronger expres-
sion  of  β-Catenin,  bcl-2,  p53  and  Ki-67  has
been  found  in  SCC.39,43-47 Studies  on  flow
cytometry (DNA index and proliferative index)
and  DNA  image  cytometry,48,49 as  well  as
immunohistochemical  expression  of  cyclins,
cyclin-dependent  kinases, oncostatin  M, β-2-
microglobulin and p16 did not show statistical
differences between KAs and SCCs.50-53
In our study, we observed that IMP-3 is not
homogenously  expressed  in  any  group  of
lesions  studied,  although  73%  of  KAs  were
IMP-3 negative and 57% of SCCs were positive.
The percentage of positive squamous cell car-
cinomas reflects data reported in the literature
on SCC of head and neck16 (61%) and tongue17
(77%),  supporting  the  hypothesis  of  IMP-3
involvement  in  malignancies.  IMP-3  expres-
sion in SCC of the oral cavity has been shown
to correlate to tumor stage, nodal stage and
overall  survival.  Among  positive  cases,  we
observed a great variability in terms of per-
centage of positive cells and staining intensity
that was unrelated to diameter of the lesion,
ulceration,  Clark  level  or  depth  of  invasion.
Our study did not include long-term follow-up
data.  Consequently  we  could  not  associate
IMP-3 expression with a less favorable clinical
outcome.
IMP-3 in KA has never been studied. Our
finding of 73% of negative cases strongly con-
trasts with SCC data. If we assume that IMP-3
has a role in carcinogenesis, this would sug-
gest the benign nature of KA. Weedon et al.
recently showed that SCC transformation may
occur in KA in up to 5.7% of cases, rising to
13.9% in the elderly (patients older than 90
years).54 We may hypothesize that basal IMP-3
expression at the tumor-stroma interface could
indicate a potential different biological behav-
ior in these tumors, at least in cases showing
a continuous and stronger positivity. Complete
excision of the lesion, in the absence of long-
term follow-up, limits the understanding of the
meaning of these preliminary data. 
Questions  about  the  classification  and
nature  of  keratoacanthoma  still  have  to  be
answered. Given these findings, in our opinion
IMP-3  expression  may  be  useful  in  distin-
guishing KA from SCC, but it is not a specific
discriminator in cases with overlapping fea-
tures.  Further  studies  in  broader  series  or
combining multiple markers are needed to bet-
ter understand the role of IMP-3 in skin squa-
mous cell tumors.
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